Iran (Islamic Republic of) vs Zambia: Percentage of bloodstream infection due to Escherichia coli resistant
Iran (Islamic Republic of)
70.6%
in 2022
Zambia
76.5%
in 2022
Iran (Islamic Republic of) rank
7th
Zambia rank
6th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Iran (Islamic Republic of)
- Zambia
How they compare
Zambia currently reports 76.5% against 70.6% in Iran (Islamic Republic of), a difference of 5.9%.
That makes Zambia's figure about 1.1 times Iran (Islamic Republic of)'s.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Iran (Islamic Republic of) ahead.
Iran (Islamic Republic of) ranks 7th and Zambia ranks 6th of 50 countries.
Across the 2 decades both report, Iran (Islamic Republic of) averaged higher in 1 and Zambia in 1.
Head to head by decade
| Decade | Iran (Islamic Republic of) | Zambia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 80.2% | 57.5% | 22.7% | Iran (Islamic Republic of) |
| 2020s | 70.0% | 88.4% | 18.4% | Zambia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Iran (Islamic Republic of) or Zambia?
- Zambia, at 76.5% against 70.6% in Iran (Islamic Republic of) as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Iran (Islamic Republic of) and Zambia?
- 5.9%, with Zambia ahead.
- How many years of comparable data are there for Iran (Islamic Republic of) and Zambia?
- 5 years are reported by both, from 2017 to 2022.
- How do Iran (Islamic Republic of) and Zambia rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Iran (Islamic Republic of) ranks 7th and Zambia ranks 6th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.